Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFRN |
Texto Completo: | https://repositorio.ufrn.br/jspui/handle/123456789/25418 http://dx.doi.org/10.1007/s11126-012-9233-3 |
Resumo: | This cross-sectional study aimed to compare the effects of treatment with an atypical antipsychotic drug (olanzapine or risperidone) on quality of life (QoL) and to document adverse effects in 115 patients diagnosed with schizophrenia who attended the ambulatory service of Hospital Dr. João Machado, Natal, Rio Grande do Norte, Brazil. Socioeconomic, sociodemographic, and clinical variables were compared. The QoL Scale validated for Brazil (QLS-BR) was used to evaluate QoL, and adverse effects were assessed using the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale. Data were analyzed using the χ2 test and Student’s t test, with a significance level of 5 %. Patients in both drug groups showed severe impairment in the occupational domain of the QLS-BR. Global QLS-BR scores indicated impairment among risperidone users and severe impairment among olanzapine users. The most significant side effects were associated with risperidone, including asthenia/lassitude/fatigue, somnolence/sedation, paresthesia, change in visual accommodation, increased salivation, diarrhea, orthostatic posture, palpitations/tachycardia, erythema, photosensitivity, weight loss, galactorrhea, decreased sexual desire, erectile/orgasmic dysfunction, vaginal dryness, headache, and physical dependence. QoL was impaired in patients using olanzapine and in those using risperidone. Risperidone use was associated with psychic, neurological, and autonomous adverse effects and other side effects. |
id |
UFRN_50873dff70f5d72c7b9047330de8707a |
---|---|
oai_identifier_str |
oai:https://repositorio.ufrn.br:123456789/25418 |
network_acronym_str |
UFRN |
network_name_str |
Repositório Institucional da UFRN |
repository_id_str |
|
spelling |
Araújo, Aurigena Antunes deChaves, Katarina MeloSerrano-Blanco, AntoniRibeiro, Susana BarbosaSoares, Luiz Alberto LiraGuerra, Gerlane Coelho BernardoAlves, Maria do Socorro Costa FeitosaAraújo Júnior, Raimundo Fernandes deRachetti, Vanessa de Paula SoaresFilgueira Júnior, Antônio2018-06-16T11:41:20Z2018-06-16T11:41:20Z2012-07-18ARAÚJO, Aurigena Antunes de et al. Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. Psychiatric Quarterly, v. 84, p. 125-135, 2012. Disponível em: <https://link.springer.com/article/10.1007%2Fs11126-012-9233-3>. Acesso em: 15 mar. 2018.1573-6709https://repositorio.ufrn.br/jspui/handle/123456789/25418http://dx.doi.org/10.1007/s11126-012-9233-3porSpringerSchizophreniaAtypical antipsychoticQuality of lifeQuality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophreniainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleThis cross-sectional study aimed to compare the effects of treatment with an atypical antipsychotic drug (olanzapine or risperidone) on quality of life (QoL) and to document adverse effects in 115 patients diagnosed with schizophrenia who attended the ambulatory service of Hospital Dr. João Machado, Natal, Rio Grande do Norte, Brazil. Socioeconomic, sociodemographic, and clinical variables were compared. The QoL Scale validated for Brazil (QLS-BR) was used to evaluate QoL, and adverse effects were assessed using the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale. Data were analyzed using the χ2 test and Student’s t test, with a significance level of 5 %. Patients in both drug groups showed severe impairment in the occupational domain of the QLS-BR. Global QLS-BR scores indicated impairment among risperidone users and severe impairment among olanzapine users. The most significant side effects were associated with risperidone, including asthenia/lassitude/fatigue, somnolence/sedation, paresthesia, change in visual accommodation, increased salivation, diarrhea, orthostatic posture, palpitations/tachycardia, erythema, photosensitivity, weight loss, galactorrhea, decreased sexual desire, erectile/orgasmic dysfunction, vaginal dryness, headache, and physical dependence. QoL was impaired in patients using olanzapine and in those using risperidone. Risperidone use was associated with psychic, neurological, and autonomous adverse effects and other side effects.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRNinstname:Universidade Federal do Rio Grande do Norte (UFRN)instacron:UFRNTEXTQuality of Life and Adverse Effects of Olanzapine_2013.pdf.txtQuality of Life and Adverse Effects of Olanzapine_2013.pdf.txtExtracted texttext/plain29140https://repositorio.ufrn.br/bitstream/123456789/25418/3/Quality%20of%20Life%20and%20Adverse%20Effects%20of%20Olanzapine_2013.pdf.txt89c54f44dd5313b47ae527080965ccedMD53THUMBNAILQuality of Life and Adverse Effects of Olanzapine_2013.pdf.jpgQuality of Life and Adverse Effects of Olanzapine_2013.pdf.jpgIM Thumbnailimage/jpeg6155https://repositorio.ufrn.br/bitstream/123456789/25418/4/Quality%20of%20Life%20and%20Adverse%20Effects%20of%20Olanzapine_2013.pdf.jpg185995c3e924d070e28b81363a784490MD54ORIGINALQualityLifeAdverseEffects_Araujo_2013.pdfQualityLifeAdverseEffects_Araujo_2013.pdfapplication/pdf199736https://repositorio.ufrn.br/bitstream/123456789/25418/1/QualityLifeAdverseEffects_Araujo_2013.pdf5e8f3cd29745cc2a999af56c4e9476e5MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.ufrn.br/bitstream/123456789/25418/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52123456789/254182021-11-11 16:56:47.158oai:https://repositorio.ufrn.br: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Repositório de PublicaçõesPUBhttp://repositorio.ufrn.br/oai/opendoar:2021-11-11T19:56:47Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)false |
dc.title.pt_BR.fl_str_mv |
Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia |
title |
Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia |
spellingShingle |
Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia Araújo, Aurigena Antunes de Schizophrenia Atypical antipsychotic Quality of life |
title_short |
Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia |
title_full |
Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia |
title_fullStr |
Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia |
title_full_unstemmed |
Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia |
title_sort |
Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia |
author |
Araújo, Aurigena Antunes de |
author_facet |
Araújo, Aurigena Antunes de Chaves, Katarina Melo Serrano-Blanco, Antoni Ribeiro, Susana Barbosa Soares, Luiz Alberto Lira Guerra, Gerlane Coelho Bernardo Alves, Maria do Socorro Costa Feitosa Araújo Júnior, Raimundo Fernandes de Rachetti, Vanessa de Paula Soares Filgueira Júnior, Antônio |
author_role |
author |
author2 |
Chaves, Katarina Melo Serrano-Blanco, Antoni Ribeiro, Susana Barbosa Soares, Luiz Alberto Lira Guerra, Gerlane Coelho Bernardo Alves, Maria do Socorro Costa Feitosa Araújo Júnior, Raimundo Fernandes de Rachetti, Vanessa de Paula Soares Filgueira Júnior, Antônio |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Araújo, Aurigena Antunes de Chaves, Katarina Melo Serrano-Blanco, Antoni Ribeiro, Susana Barbosa Soares, Luiz Alberto Lira Guerra, Gerlane Coelho Bernardo Alves, Maria do Socorro Costa Feitosa Araújo Júnior, Raimundo Fernandes de Rachetti, Vanessa de Paula Soares Filgueira Júnior, Antônio |
dc.subject.por.fl_str_mv |
Schizophrenia Atypical antipsychotic Quality of life |
topic |
Schizophrenia Atypical antipsychotic Quality of life |
description |
This cross-sectional study aimed to compare the effects of treatment with an atypical antipsychotic drug (olanzapine or risperidone) on quality of life (QoL) and to document adverse effects in 115 patients diagnosed with schizophrenia who attended the ambulatory service of Hospital Dr. João Machado, Natal, Rio Grande do Norte, Brazil. Socioeconomic, sociodemographic, and clinical variables were compared. The QoL Scale validated for Brazil (QLS-BR) was used to evaluate QoL, and adverse effects were assessed using the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale. Data were analyzed using the χ2 test and Student’s t test, with a significance level of 5 %. Patients in both drug groups showed severe impairment in the occupational domain of the QLS-BR. Global QLS-BR scores indicated impairment among risperidone users and severe impairment among olanzapine users. The most significant side effects were associated with risperidone, including asthenia/lassitude/fatigue, somnolence/sedation, paresthesia, change in visual accommodation, increased salivation, diarrhea, orthostatic posture, palpitations/tachycardia, erythema, photosensitivity, weight loss, galactorrhea, decreased sexual desire, erectile/orgasmic dysfunction, vaginal dryness, headache, and physical dependence. QoL was impaired in patients using olanzapine and in those using risperidone. Risperidone use was associated with psychic, neurological, and autonomous adverse effects and other side effects. |
publishDate |
2012 |
dc.date.issued.fl_str_mv |
2012-07-18 |
dc.date.accessioned.fl_str_mv |
2018-06-16T11:41:20Z |
dc.date.available.fl_str_mv |
2018-06-16T11:41:20Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
ARAÚJO, Aurigena Antunes de et al. Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. Psychiatric Quarterly, v. 84, p. 125-135, 2012. Disponível em: <https://link.springer.com/article/10.1007%2Fs11126-012-9233-3>. Acesso em: 15 mar. 2018. |
dc.identifier.uri.fl_str_mv |
https://repositorio.ufrn.br/jspui/handle/123456789/25418 |
dc.identifier.issn.none.fl_str_mv |
1573-6709 |
dc.identifier.doi.none.fl_str_mv |
http://dx.doi.org/10.1007/s11126-012-9233-3 |
identifier_str_mv |
ARAÚJO, Aurigena Antunes de et al. Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. Psychiatric Quarterly, v. 84, p. 125-135, 2012. Disponível em: <https://link.springer.com/article/10.1007%2Fs11126-012-9233-3>. Acesso em: 15 mar. 2018. 1573-6709 |
url |
https://repositorio.ufrn.br/jspui/handle/123456789/25418 http://dx.doi.org/10.1007/s11126-012-9233-3 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Springer |
publisher.none.fl_str_mv |
Springer |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRN instname:Universidade Federal do Rio Grande do Norte (UFRN) instacron:UFRN |
instname_str |
Universidade Federal do Rio Grande do Norte (UFRN) |
instacron_str |
UFRN |
institution |
UFRN |
reponame_str |
Repositório Institucional da UFRN |
collection |
Repositório Institucional da UFRN |
bitstream.url.fl_str_mv |
https://repositorio.ufrn.br/bitstream/123456789/25418/3/Quality%20of%20Life%20and%20Adverse%20Effects%20of%20Olanzapine_2013.pdf.txt https://repositorio.ufrn.br/bitstream/123456789/25418/4/Quality%20of%20Life%20and%20Adverse%20Effects%20of%20Olanzapine_2013.pdf.jpg https://repositorio.ufrn.br/bitstream/123456789/25418/1/QualityLifeAdverseEffects_Araujo_2013.pdf https://repositorio.ufrn.br/bitstream/123456789/25418/2/license.txt |
bitstream.checksum.fl_str_mv |
89c54f44dd5313b47ae527080965cced 185995c3e924d070e28b81363a784490 5e8f3cd29745cc2a999af56c4e9476e5 8a4605be74aa9ea9d79846c1fba20a33 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN) |
repository.mail.fl_str_mv |
|
_version_ |
1797777062773129216 |